Biocept (BIOC) Reports Q3 Loss of $0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Biocept (BIOC) Reports Q3 Loss of $0.24
November 5, 2015 4:05 PM EST
SAN DIEGO, Nov. 5, 2015 /PRNewswire/ --Â Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of cancer, today reported financial results for the three and nine months ended September 30, 2015, and provided an update on business progress.Â
"During the third quarter we launched proprietary quantitative assays that target important mutations in colorectal cancer, melanoma and small cell lung cancer, building on what we believe to be the largest... More
November 5, 2015 7:00 AM EST
Data for the detection and monitoring of key predictive biomarkers
for patients with newly diagnosed or progressing metastatic lung cancer
on therapy to be presented at the Association for Molecular Pathology
Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company
commercializing and developing biomarkers used in liquid biopsies to
improve the detection and treatment of cancer, today announced that
findings demonstrating the ability to reliably detect actionable genetic
alterations used in the diagnosis, monitoring and treatment of patients
with lung cancer using its... More
